Literatur
- 1
American College of Cardiology/American Heart Association .
ACC/AHA guidelines for the evaluation and management of chronic heart failure in the
adult.
J Heart Lung Transplant.
2002;
21
189-203
- 2 Arzneimittelkommission der deutschen Ärzteschaft .Chronische Herzinsuffizienz. Empfehlungen
zur Therapie der chronischen Herzinsuffizienz. Gemeinsame Empfehlung mit der Deutschen
Gesellschaft für Kardiologie - Herz- und Kreislaufforschung. AVP-Sonderheft Therapieempfehlungen,
2. Aufl. 2001
- 3 The 2002/3 Canadian cardiovascular society consensus guideline. http://www.ccs.ca/download/CCSHFConsUpdateDraft0103EMail.pdf
- 4
Hoppe U C, Erdmann E. für die Kommission Klinische Kardiologie .
Leitlinien zur Therapie der chronischen Herzinsuffizienz. Herausgegeben von der Deutschen
Gesellschaft für Kardiologie- Herz- und Kreislaufforschung.
Z Kardiol.
2001;
90
218-237
- 5 Kaiser T, Jennen E, Sawicki P T. Entscheidungsgrundlage zur evidenzbasierten Diagnostik
und Therapie bei Disease Management Programmen für Herzinsuffizienz bei systolischer
linksventrikulärer Dysfunktion. 2., überarbeitete Version. Institut für evidenzbasierte
Medizin 2003
- 6 The Finnish Medical Society Duodecim .Chronic heart failure. Duodecim 2004. www.ebm-guidelines.com
- 7 Department of Veterans Affairs & Veterans Health Administration .The pharmacologic
management of chronic heart failure. Pharmacy benefits management strategic healthcare
group and the medical advisory panel, Veterans Health Administration, Department of
Veterans Affairs. Washington, DC 2001; updated December 2002. PBM-MAP Publication
No. 00-0015. http://www.oqp.med.va.gov/cpg/CHF/CHF_Base.htm
- 8
Remme W J, Swedberg K.
Comprehensive guidelines for the diagnosis and treatment of chronic heart failure.
Task force for the diagnosis and treatment of chronic heart failure of the European
Society of Cardiology.
Eur J Heart Fail.
2002;
4
11-22
- 9 Institute for Clinical System Improvement .Health care guideline. Congestive heart
failure in adults. 2003. http://www.icsi.org/knowledge/detail.asp?catID = 29&itemID
= 161
- 10
Schubert I. General Practitioners' Guideline Group of Hessen .
[Guideline report of the Guideline Group of Hessen - general practice therapy circle:
management of chronic heart failure].
Z Ärztl Fortbild Qualitätssich.
2003;
97
145-150
- 11 National Heart Foundation of Australia and Cardiac Society of Australia & New Zealand
.Guidelines on the Contemporary management of the patient with chronic heart failure
in australia. 2002. http://www.new.heartfoundation.com.au/downloads/cont.management.pdf
- 12 The National Heart Foundation of New Zealand .A guideline for the management of
heart failure. 2001. http://www.nzgg.org.nz/guidelines/dsp_guideline_popup.cfm?guidelineCatID
= 32&guidelineID = 26
- 13 The National Collaborating Centre for Chronic Conditions .Chronic heart failure.
National clinical guideline for diagnosis and management in primary and secondary
care. NICE Guide-line No. 5. National Institute for Clinical Excellence 2003; http://www.nice.org.uk
- 14 Ontario Program for Optimal Therapeutics .Ontario drug therapy guidelines for chronic
heart failure in primary care. 2000. http://www.opot.org/guidelines/chf.pdf
- 15 Chavey W E, Blaum C S, Bleske B E, Harrison R Van, Kesterson S, Nicklas J M. Guideline
for the management of heart failure caused by systolic dysfunction: Part I. Guideline
developement, etiology and diagnosis. Part II. Treatment. University of Michigan,
American Family Physician 2001; 769-774, 1045-1054
- 16 Universität Witten/Herdecke .Leitlinie Diagnose und Therapie der chronischen Herzinsuffizienz. 2001.
http://www.evidence.de/Leitlinien/leitlinien-intern/Herzinsuffizienz_Start/herzinsuffizienz_start.html
- 17
Jessup M, Brozena S.
Heart failure.
N Engl J Med.
2003;
348
2007-2018
- 18
Piepoli M F, Davos C, Francis D P. et al .
ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with
chronic heart failure (ExTraMATCH).
BMJ.
2004;
328
189
- 19 Andrews R, Dear K, Holden J. et al .Vaccines for preventing pneumococcal infection
in adults (Review). The Cochrane Database of Systematic Reviews 2003, Issue 3. Art.
No.: CD000422. DOI: 10.1002/14651858. CD000422
- 20 Shekelle P, Rich M, Morton S. et al .Pharmacologic management of heart failure
and left ventricular systolic dysfunction: effect in female, black, and diabetic patients,
and cost effectiveness. Evidence Report/Technology Assessment No. 82 (Prepared by
the Southern California-RAND Evidence-based Center under contract No 290-97-0001).
AHRQ Publication No. 03-E045. Agency for Healthcare Research and Quality, Rockville,
MD 2003; Im Internet erhältlich: http://www.ahrq.gov/
- 21
Packer M, Poole-Wilson P A, Armstrong P W. et al on behalf of the ATLAS Study Group
.
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor,
Lisinopril, on morbidity and mortality in chronic heart failure.
Circulation.
1999;
100
2312-2318
- 22
Bonet S, Agustí A, Arnau J M. et al .
[beta]-adrenergic blocking agents in heart failure: benefits of vasodilating and nonvasodilating
agents according to patients’ characteristics: A meta-analysis of clinical trials.
Arch Intern Med.
2000;
160
621-627
- 23
Bouzamondo A, Hulot J S, Sanchez P. et al .
Beta-blocker treatment in heart failure.
Fundamental & Clinical Pharmacology.
2001;
15
95-109
- 24
Brophy J M, Joseph L, Rouleau J L.
β-Blockers in congestive heart failure. A Bayesian meta-analysis.
Ann Intern Med.
2001;
134
550-560
- 25
Dimopoulos K, Salukhea T V, Coats A JS. et al .
Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker
in patients with chronic heart failure already receiving an ACE inhibitor (alone or
with a β-blocker).
Intern J Cardiol.
2004;
93
105-111
- 26
Jong P, Demers C, McKelvie R S. et al .
Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled
trials.
J Am Coll Cardiol.
2002;
39
463-470
- 27
Pfeffer M A, McMurray J JV, Velazquez E J. et al for the Valsartan in Acute Myocardial
Infarction Trial Investigators .
Valsartan, Captopril, or both in myocardial infarction complicated by heart failure,
left ventricular dysfunction, or both.
N Engl J Med.
2003;
349
1893-906
- 28
Pitt B, Zannad F, Remme W J. et al .
The effect of spironolactone on morbidity and mortality in patients with severe heart
failure: Randomized Aldactone Evaluation Study Investigators.
N Engl J Med.
1999;
341
709-717
- 29
Juurlink D N, Mamdani M M, Lee D S. et al .
Rates of hyperkalemia after publication of the randomized Aldactone evaluation study.
N Engl J Med.
2004;
351
543-551
- 30 Marciniak T. FDA Medical Review. Application number 21-437/S-002. sNDA 21-437 Inspra™
Tablets. Pharmacia Corporation. http://www.fda.gov/cder/foi/nda/2003/21-437s002_Inspra.htm
- 31
Rathore S S, Wang Y, Krumholz H M.
Sex-based differences in the effect of digoxin for the treatment of heart failure.
N Engl J Med.
2002;
347
1403-1411
- 32
Adams K F, Gheorghiade M, Uretsky B F. et al .
Clinical benefits of low serum digoxin concentrations in heart failure.
J Am Coll Cardiol.
2002;
39
946-953
- 33
Khand A U, Rankin A C, Kaye G C. et al .
Systematic review of the management of atrial fibrillation in patients with heart
failure.
European Heart J.
2000;
21
614-632
- 34 Lip G YH, Gibbs C R. Anticoagulation for heart failure in sinus rhythm (Cochrane
Review). In: The Cochrane Library, Issue 1, 2004. John Wiley & Sons, Ltd., Chichester,
UK 2004
- 35
Gensichen J, Beyer M, Küver C. et al .
Case Management für Patienten mit Herzinsuffizienz in der ambulanten Versorgung -
Ein kritischer Review.
Z ärztl Fortbild Qualitätssich.
2004;
98
143-154
- 36
Stellbrink C, Auricchio A, Lemke B. et al .
Positionspapier zur kardialen Resynchronisationstherapie.
Z Kardiol.
2003;
92
96-103
- 37
Bradley D J, Bradley E A, Baughman K L. et al .
Cardiac resynchronization and death from progressive heart failure. A metaanalysis
of randomised controlled trials.
JAMA.
2003;
289
730-740
- 38
Bristow M R, Saxon L A, Boehmer J. et al .
Cardiac-resynchronization therapy with or without an implantable defibrillator in
advanced chronic heart failure.
N Engl J Med.
2004;
350
2140-2150
- 39
Parkes J, Bryant J, Milne R.
Implantable cardioverters defibrillators: arrhythmias. A rapid and systematic review.
Health Technology Assessment.
2000;
4
1-69
- 40 Empfehlungen der ständigen Impfkommission (STIKO) am Robert-Koch-Institut Stand
Juli 2005. Epidemiologisches Bulletin 29. Juli 2005, Nr. 30. http://www.bundesärztekammer.de/30/Richtlinien/Empfidx/stiko.pdf
1 Leitlinienentwicklung in Kooperation mit dem Kompetenznetz Herzinsuffizienz und der
Deutschen Gesellschaft für Allgemeinmedizin, DEGAM; Förderung durch das BMBF, Förderkennzeichen:
01GI0205.
Christiane MuthMPH
Institut für Allgemeinmedizin · Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
am Main
Theodor-Stern-Kai 7
60590 Frankfurt am Main
Email: Muth@allgemeinmedizin.uni-frankfurt.de
